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http://www.biomedcentral.com/1471-2474/14/349RESEARCH ARTICLE Open AccessAnalysis of mass spectrometry data from the
secretome of an explant model of articular
cartilage exposed to pro-inflammatory and
anti-inflammatory stimuli using machine learning
Anna L Swan1, Kirsty L Hillier2, Julia R Smith3, David Allaway4, Susan Liddell1,5,7, Jaume Bacardit6,7,8†
and Ali Mobasheri2,7,9,10,11,12,13,14,15*†Abstract
Background: Osteoarthritis (OA) is an inflammatory disease of synovial joints involving the loss and degeneration
of articular cartilage. The gold standard for evaluating cartilage loss in OA is the measurement of joint space width
on standard radiographs. However, in most cases the diagnosis is made well after the onset of the disease, when
the symptoms are well established. Identification of early biomarkers of OA can facilitate earlier diagnosis, improve
disease monitoring and predict responses to therapeutic interventions.
Methods: This study describes the bioinformatic analysis of data generated from high throughput proteomics for
identification of potential biomarkers of OA. The mass spectrometry data was generated using a canine explant
model of articular cartilage treated with the pro-inflammatory cytokine interleukin 1 β (IL-1β). The bioinformatics
analysis involved the application of machine learning and network analysis to the proteomic mass spectrometry
data. A rule based machine learning technique, BioHEL, was used to create a model that classified the samples into
their relevant treatment groups by identifying those proteins that separated samples into their respective groups.
The proteins identified were considered to be potential biomarkers. Protein networks were also generated; from
these networks, proteins pivotal to the classification were identified.
Results: BioHEL correctly classified eighteen out of twenty-three samples, giving a classification accuracy of 78.3%
for the dataset. The dataset included the four classes of control, IL-1β, carprofen, and IL-1β and carprofen together.
This exceeded the other machine learners that were used for a comparison, on the same dataset, with the
exception of another rule-based method, JRip, which performed equally well. The proteins that were most
frequently used in rules generated by BioHEL were found to include a number of relevant proteins including
matrix metalloproteinase 3, interleukin 8 and matrix gla protein.
Conclusions: Using this protocol, combining an in vitro model of OA with bioinformatics analysis, a number of
relevant extracellular matrix proteins were identified, thereby supporting the application of these bioinformatics
tools for analysis of proteomic data from in vitro models of cartilage degradation.
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Articular cartilage is a mechanically resilient connective
tissue with unique load-bearing and shock-absorbing
properties, which are largely dependent on the structural
and functional integrity of its highly charged and hy-
drated extracellular matrix (ECM) [1]. Cartilage contains
three principal components: chondrocytes, aggregating
proteoglycans and collagens, all of which are embedded
within the ECM and contribute to the homeostasis of
the tissue [2]. Cartilage relies on oxygen and nutrient de-
livery from the synovial fluid [3] but is avascular and re-
calcitrant to repair [4]. Osteoarthritis (OA) is a
degenerative disease of synovial joints, involving the loss
of articular cartilage, synovial inflammation and changes
to the subchondral bone, resulting in impaired articula-
tion, reduced mobility, joint stiffness and pain [5,6]. OA
is estimated to affect up to 85% of the human population
over 60 years old [7] and is also common in companion
animals [8]. There are a number of factors affecting OA,
including age, obesity, previous joint trauma or instabil-
ity, metabolic or endocrine disease and oestrogen status
[9,10]. Currently, diagnosis is made through clinical
examination and the imaging “gold standard”, radiog-
raphy. However, radiographic diagnosis of OA is usually
made when the clinical signs of pain and loss of mobility
have already appeared. Consequently, the disease can re-
main undiagnosed until the later stages, where interven-
tions may not alter the course of progression.
Biomarkers have the capacity to identify early changes
in joint tissues and diagnose OA during the pre-
radiographic stages of the disease and to determine the
course of its progression, as well as aid in drug discovery
and clinical trials [11-15]. The term biomarker can be
used to describe molecules or molecular fragments that
indicate the presence of a biological or disease process.
Early detection may also help prioritize treatments to
slow progression, such as weight loss and a reduction in
high impact load bearing on those joints [16]. Therefore,
individual or combination biomarkers must be able to
clearly differentiate between healthy and diseased states.
Ideally biomarkers should be disease-specific and not be
influenced by other disorders. Biomarkers should also be
easily measurable in a clinical setting [17]. In rheumatol-
ogy, biomarkers can be “tissue fingerprints” or combina-
tions of “neo-epitopes”, reflecting catabolic effects
downstream of inflammatory signals.
Recent advances in post-genomic technologies, includ-
ing genomics, transcriptomics, proteomics and metabo-
lomics, have allowed the development of novel methods
for identification of biomarkers of disease. Proteomics is
a particularly promising technology as it allows the iden-
tification of individual proteins and their peptides,
neo-epitopes and degradation “fingerprints”. This infor-
mation can then be used to develop sensitive, rapidantibody-based assays. In addition proteomic analyses
provide an overview of changes in the proteome in bio-
logical systems across a range of conditions [18].
Through the combined use of proteomics, transcripto-
mics and other biochemical and immunological tech-
niques, a number of proteins and protein families have
previously been associated with OA. These include ECM
proteins such as aggrecan, the major structural proteo-
glycan found in the cartilage ECM, cartilage oligomeric
matrix protein (COMP), a non-collagenous protein in-
volved in the organization and assembly of articular car-
tilage, and matrix metalloproteinases (MMPs), a family
of proteins expressed by chondrocytes, which are in-
volved in the degradation of ECM macromolecules and
lead to the fibrillation of articular cartilage [11,19-24]. In
the ECM, matrix metalloproteinase-3 (MMP-3) in par-
ticular appears to be vital for matrix turnover and
homeostasis. This protein is up-regulated in early OA,
but has been found to be down-regulated in later stages
of the disease [25].
Many omics technologies, such as microarrays, next
generation sequencing and mass spectrometry (MS),
generate large amounts of data. Therefore, bioinformatic
tools play an important role in the analysis of such data
and a wide range of methods have been developed for
this purpose [26,27]. Supervised machine learning tech-
niques are used, based on a training set of labelled sam-
ples, to build models that are able to automatically label
previously unclassified samples [28,29]. Samples can be
assigned a label (e.g. a treatment group) based on
whether or not they contain a certain attribute (e.g. a
protein, or a group of proteins) and at what level the at-
tribute is found within the samples [30,31]. There are
many types of machine learning techniques, such as de-
cision trees, rule-based learners and support vector ma-
chines [28,32]. Rule-based machine learning methods
automatically produce human-readable production rules
that assign samples to their respective treatment groups.
In proteomics-based approaches, the rules created con-
tain proteins that best divide the samples into disease or
treatment groups. Proteins most consistently differing
between groups are suitable for further investigation as
potential biomarkers.
The aim of this study was to identify suitable bioinfor-
matic methods for the analysis of proteomics data gener-
ated to investigate cytokine-induced catabolic changes
associated with the early stages of OA [33]. This in-
volved using an explant model of cartilage to investigate
the secretome of canine articular cartilage. The cartilage
explant model was selected because it allows a rapid and
‘clean’ analysis of secreted proteins in the context of
joint disease. Many of the proteins present in the secre-
tome of explant cultures are involved in the control of
physiological and pathophysiological processes in the
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may be accessible as systemic biomarkers.
Methods
Animal tissues and statement of ethical approval
Forelimbs and hind limbs were taken from male German
Shepherd army dogs, over 5 years of age, that were eu-
thanized for clinical reasons unrelated to research.
Therefore, this project does not fall under the Animals
(Scientific Procedures) Act 1986a or the Veterinary Sur-
geons Act 1966b. Approval for the use of clinical mate-
rials was obtained from the Ethics Committee of the
School of Veterinary Science and Medicine with input
from members of the University of Nottingham's Animal
Welfare and Ethical Review Body (AWERB). The British
Army owned the animals that were used in this study. In-
formed consent was obtained for the use of joint tissues.
Cartilage explant culture
Limbs were washed in disinfectant and soaked in sodium
hypochlorite prior to spraying with ethanol. The stifle
and elbow joints were dissected under sterile conditions
and full thickness articular cartilage was placed in serum
free collection media. The media consisted of Hyclone®
liquid medium: DMEM supplemented with penicillin
and streptomycin.
After washing the harvested cartilage, a 3 mm biopsy
punch was used to cut discs, which were placed in a ran-
domized manner into wells of a 24 well plate, containing
serum free DMEM (as above). The media was removed
and the explants were incubated in media alone (con-
trol), or supplemented with recombinant canine IL-1β
(10 ng/ml), the non-steroidal anti-inflammatory drug
carprofen (Rimadyl®, 100 μg/ml), or carprofen and IL-1β
combined (100 μg/ml and 10 ng/ml, respectively). For
each treatment, three samples were used per dog, giving
six samples per treatment. After 5 days in culture, super-
natants and explants were removed and processed for
mass spectrometric analysis.
Sample preparation and mass spectrometry
Samples from 2 dogs were chosen for MS/MS analysis
based on the general profile of proteins as visualized on
SDS-PAGE (data not included in the manuscript, see
Additional file 1: Table S1; Additional file 2: Table S2;
Additional file 3: Table S3; Additional file 4: Table S4;
Additional file 5: Figure S1; Additional file 6: Figure S2).
Each set of dog samples consisted of three treatments
(IL-1β, carprofen, IL-1β + carprofen), with three repli-
cates for each treatment for both dogs. A set of control
samples was also analyzed, providing a total of 24 sam-
ples (12 samples per dog).
The secretome samples were digested with trypsin be-
fore mass spectrometry. Soluble proteins were reducedby the addition of DTT to a final concentration of
10 mM to each sample. The thiol groups were blocked
by the addition of iodoacetamide to a final concentration
of 55 mM. The proteins were then precipitated with ice-
cold acetone before being suspended in trypsin solution
(10 ng/μl in 50 mM ammonium bicarbonate) (Trypsin
Gold, Mass Spectrometry Grade, Promega). Trypsin di-
gestion was terminated by addition of formic acid to give
a final concentration of 0.1%. Before MS analysis, an
aliquot of the digestion was desalted and any insoluble
particulates removed using a C18 Zip-Tip (Millipore).
Peptides were separated on a 15 cm C18 PepMap™ col-
umn (LC Packings) using a Bruker Easy-nLC platform
with a flow rate of 300 nl/min. The sample was added to
solvent A (95% v/v H2O, 5% v/v ACN, 0.1% v/v formic
acid) and was injected into the HPLC column via the
autosampler. Following binding and washing of the sam-
ple on the column in solvent A, peptides were separated
and eluted in a gradient of solvent B (95% v/v ACN,
5% v/v H2O, 0.1% v/v formic acid).
Eluted peptides were delivered on-line and detected in
a Bruker AmaZon ETD ion trap instrument. The five
most abundant peptides in each MS scan were selected
for fragmentation. The raw data were processed to pro-
vide peptide and fragment mass lists which were submit-
ted to the MS/MS ions tool of the Mascot search
engine, software which uses protein sequence databases
to predict the identity of proteins present in samples,
based on the peptides identified. The fragment mass
values for each peptide were compared to the mam-
malian entries from the UniProtKB database. The mo-
difications incorporated into the search were: fixed
carbamidomethyl cysteine and variable oxidation of
methionine.
One sample, treated with both IL-1β + carprofen, was
removed from the dataset at this stage as it was consid-
ered to be anomalous due to the very small number of
proteins that were identified from it by Mascot. This re-
sulted in 23 samples for further analysis: six samples per
treatment, except for IL-1β + carprofen, for which there
were five samples.
Further MS data analysis pipeline
The pipeline for the analysis of mass spectrometry data
is described in Figure 1. Included in the results gener-
ated by Mascot is the exponentially modified protein
abundance index (emPAI) score for each protein identi-
fied. The emPAI score gives an estimate for the absolute
amount of a protein present in a sample [35]. It is based
on the protein abundance index (PAI), which is defined
as ‘the number of peptides identified divided by the
number of theoretically observable tryptic peptides’ [36].
PAI was then adapted to emPAI to ensure it is propor-
tional to the total protein content in a sample [35].
Bruker mass 
spectrometry data
Mascot database 
search using 
UniprotKB
Extract
emPAI scores
ProteinProphet 
[TPP]
Extract
ProteinProphet scores
Machine learning
Classification using 
range of machine 
learning methods 
[WEKA] 
Classification & top 
ranking proteins 
[BioHEL]
Figure 1 Pipeline for label-free quantification of mass
spectrometry data. TPP – stages included in the Trans-Proteomic
Pipeline.
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[37,38], part of the Trans-Proteomic Pipeline [39], used
for the statistical validation of protein identifications.
Using ProteinProphet a probability score is assigned to
each of the protein identifications that was made by
Mascot. Strictly speaking, ProteinProphet is not a true
quantification method, but the probability scores that it
produces are roughly equivalent to a quantitative ap-
proach. Therefore it is suitable for further analysis using
machine learning techniques.
Both the emPAI and ProteinProphet scores were gen-
erated. Machine learning was applied to these datasets using
a number of methods from the WEKA machine learning
package [32] and BioHEL, a rule based learner [31].
Comparison of machine learning techniques
To determine the most suitable machine learning
method for the analysis of canine articular cartilage mass
spectrometry dataset, seven different machine-learningtechniques, including BioHEL, were applied to compare
their abilities. The other methods used were Naive
Bayes, Support Vector Machines, C4.5, IBk, JRip and
Random Forest, all implemented in WEKA. The source
code and user manual for BioHEL are available at http://
ico2s.org/software/biohel.html.
Due to some anomalous identifications in the Mascot
results for one of the carprofen + IL-1β samples, where
only a very small number of proteins were identified
compared to the other samples, it was removed from the
dataset. This resulted in a dataset of 23 samples, span-
ning four treatment classes. As a result of this small
number of samples, leave-one-out cross validation was
used to divide them into training and test sets [40];
using this method allows for the most information to be
extracted from the data available. Twenty-three training
sets and the same number of test sets were created. The
test sets each contained only one sample, with the re-
mainder of the dataset in the related training set. This
allows the ability of classification models to be
evaluated.Significance testing
The significance of the BioHEL classification accuracies
achieved was tested by calculating p-values using one-
tailed permutation testing [41]. A new version of the
dataset was created where the samples were randomly
assigned to treatments, but maintaining the same num-
ber of samples per treatment as in the original data.
Afterwards, BioHEL was run, using leave-one-out cross-
validation, to compare the accuracies achieved; 50 such
permutations were generated for the emPAI, ProteinPro-
phet and combined datasets. The accuracies achieved by
these runs were compared to the accuracies achieved on
the real, non-randomized, datasets and a p-value of the
likelihood that the accuracy on the original data belongs
to the randomized distribution was computed.Identification of top ranking proteins
Due to the performance of BioHEL in the comparison
with other machine learning methods, analyses using
BioHEL continued through the identification of proteins
that were pivotal to the classification, using a method-
ology previously used for the analysis of transcriptomics
data [42,43].
BioHEL classifies samples by automatically producing
rules sets that consist of a number of rules that use the
proteins found in the samples to determine which treat-
ment group they belong to. Each rule within a set uses
proteins, when used with mass spectrometry data, to as-
sign samples to treatment classes. A rule within a set
uses one or more proteins and assigns samples to the
relevant class, shown at the end of rule, if it matches
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ample of a rule set for this data follows:
1. If the abundance of TPIS is greater than 0.01 then
the sample belongs to the IL-1β group
2. If the abundance of IL-8 is greater than 0.02 then
the sample belongs to the carprofen+IL-1β group
3. If the abundance of MMP-3 is greater than 0 and the
abundance of UBIB is less than 0.2 then the sample
belongs to the IL-1β group
4. If the abundance of MGP is greater than 0 and the
abundance of A1AT is less than 0.9 then the sample
belongs to the carprofen group
5. If the abundance of ALBU is greater than 0.01 then
the sample belongs to the carprofen+IL-1β group
6. Any sample not assigned to a group belongs to the
control group
The combinations of rules in the rule sets are used to
assign samples to their respective treatment groups.
Each rule contains one or more proteins and a score
(either emPAI or ProteinProphet), which each protein
should either be above or below, depending on the sign
used. At the end of each line is the treatment class to
which each rule relates. For example, the 1st rule of the
rule set shown classifies all samples as belonging to the
IL-1β class if the value of the protein attribute TPIS is
greater than 0.01. There are no rules for the control: all
samples that are not assigned to the other three classes
by the rules generated will be, by default, considered as
a control sample.
Due to the stochastic nature of BioHEL, running it
multiple times on the same dataset produces different
rule sets. Therefore BioHEL was run 10,000 times to
analyze the results and determine recurrent patterns.
Proteins were ranked by the number of times they ap-
peared in rules across the 10,000 runs, to highlight those
proteins used most frequently. Those ranking at the top
are proteins that can be used to most successfully iden-
tify between samples of different treatments. As these
proteins are the most different between treatment clas-
ses, they may be suitable for consideration as biomarkers
or further analysis of them may provide information
about possible novel methods for diagnosis or treatment.
Network generation
To investigate interactions between proteins with our
prediction model we used network analysis, by identify-
ing proteins that were working together in rules gener-
ated by BioHEL. Within rules generated by BioHEL
protein pairs can be identified, from which networks
were generated. These networks can be used to identify
relationships between proteins; they also provide a visual
way of viewing those proteins that are frequently in rulesthrough identification of the most connected proteins.
In the example of a rule set, shown in “Identification of
top ranking proteins” subsection, there are some rules
that use more than one protein; these were used to form
protein pairs. For example, in the third rule both apoli-
poprotein E (APOE) and hyaluronan and proteoglycan
link protein 1 (HPLN1) are used and so are considered a
protein pair. The 100 protein pairs that were most fre-
quently used within rules, for each individual treatment
class, across the 10,000 runs of BioHEL were extracted
and a network was generated from them in Cytoscape
[44]. The networks consist of nodes that relate to the
proteins, found in the BioHEL rules, and edges connect
proteins if they were frequently included in rules to-
gether. The edges were then coloured based on the
treatment class that each pair of proteins relates to.
Results and discussion
Proteomic techniques are increasingly being used for
the identification of novel joint disease biomarkers
[11,19,20,45]. This study tests the hypothesis that the
secretome of canine articular cartilage may provide a
simple but well-defined model for studying potential
biomarkers of early cartilage damage. To study the
secretome of canine articular cartilage in an explant
model we used a combination of conventional and high
throughput proteomic techniques, followed by the appli-
cation of bioinformatics techniques.
Although the cartilage explant system has not been
used extensively in proteomic studies, a similar equine
explant model of articular cartilage has been used to
examine changes in the secretome in response to pro-
inflammatory and anti-inflammatory stimuli [33]. This
present study indicates that canine cartilage explants can
also serve as a model for targeted and high throughput
proteomic studies. This is supported by the identification
of a large number of proteins whose functions are rele-
vant to articular cartilage and biological processes that
are relevant to joint disease and OA. Using the explant
model this study has demonstrated it is feasible to in-
corporate pathophysiologically relevant stimuli such as
pro-inflammatory cytokines (e.g. IL-1β) to simulate cata-
bolic changes as well as NSAIDs (e.g. carprofen) to
simulate pharmacotherapy in a well-controlled model
in vitro.
The SDS-PAGE protein profiles of the IL-1β stimulated
samples illustrate that some proteins are present at a
higher level of abundance in the presence of IL-1β. This
was demonstrated by the presence of extra bands in the
IL-1β treated samples that were not detected in the con-
trols (see Additional file 1: Table S1; Additional file 2:
Table S2; Additional file 3: Table S3; Additional file 4:
Table S4; Additional file 5: Figure S1; Additional file 6:
Figure S2). There was also general consistency in protein
Table 1 Comparison of performance accuracies, as percentage of samples correctly classified, for classification of
canine articular cartilage data for seven different machine-learning methods, using leave-one-out cross-validation
Dataseter Naive Bayes SVM k-nearest neighbour JRip (rule based) Random forest C4.5 BioHEL
ProteinProphet 39.1 52.2 34.8 43.5 34.8 52.2 73.9
emPAI 52.2 56.5 52.2 78.3 39.1 73.9 56.5
ProteinProphet and emPAI combined 52.2 52.2 43.5 78.3 26.1 47.8 78.3
For the ‘ProteinProphet and emPAI combined’ the two scores were combined into one dataset. The highest accuracies achieved in each dataset are shown in bold.
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animals (see Additional file 1: Table S1; Additional file 2:
Table S2; Additional file 3: Table S3; Additional file 4:
Table S4; Additional file 5: Figure S1; Additional file 6:
Figure S2).
A range of machine learning methods were compared
and BioHEL proved to be successful in classifying both
the ProteinProphet and emPAI datasets. The accuracies
of the range of machine learning techniques tested on
the canine articular cartilage data are shown in Table 1.
For the BioHEL classifications on each dataset, confu-
sion matrices (that identify, treatment by treatment, how
the samples were predicted) were generated to under-
stand which samples were predicted correctly. It can be
seen from the matrices for the emPAI, ProteinProphet
and combined datasets (Figure 2) that the most frequent
incorrect prediction made was predicting control sam-
ples as carprofen treated samples. This is due to the
similarity between these groups, as carprofen was added
in the absence of IL-1β and thus there was no pro-
inflammatory present for this NSAID to act on. No IL-
1β sample was predicted as a control sample. FromControl
----------------
Control 1
IL-1 0
Carprofen 4
Carprofen +IL-1 0
Control
----------------
Control 2
IL-1 0
Carprofen 0
Carprofen +IL-1 0
Control
----------------
Control 3
IL-1 0
Carprofen 0
Carprofen +IL-1 0
emPAI dataset
ProteinProphet dataset
Combined dataset
R
ea
l t
re
at
m
en
t
R
ea
l t
re
at
m
en
t
R
ea
l t
re
at
m
en
t
Figure 2 Confusion matrices, for the emPAI, ProteinProphet and com
which class they were predicted to be in, using BioHEL.Table 1, it can be seen that BioHEL achieves the highest
accuracies for both the ProteinProphet and the dataset
that combines both emPAI and ProteinProphet scores;
because of this, analysis was continued using BioHEL.
The classification was increased by the combination of
these two scoring systems. The significance of the Bio-
HEL classification accuracies was supported by the p-
values, calculated using permutation testing, shown in
Table 2, as they were all close to zero. The outcome of
this test confirms that the models generated by BioHEL
(rule sets) are sound and hence we can safely analyze
them to extract rankings of important variables and gen-
erate interaction networks.
From the rules generated by BioHEL, the top ranking
mammalian proteins for the three treatments are shown
in Tables 3 and 4. There is no ranking for the control
class because it was used as the default and so did not
include any proteins in rules. The default is included at
the end of a rule set, so that any sample that has not
been assigned to a class by the rules in the set is auto-
matically placed into the default class. Table 5 shows the
top ranking mammalian proteins for the emPAI andIL-1 Carprofen Carprofen +IL-1
---------------------------------------------------------------
0 5 0
4 1 1
0 2 0
0 0 5
IL-1 Carprofen Carprofen +IL-1
--------------------------------------------------------------
0 4 0
4 0 2
0 6 0
0 0 5
IL-1 Carprofen Carprofen +IL-1
--------------------------------------------------------------
0 3 0
4 0 2
0 6 0
0 0 5
Predicted treatment
bined datasets, to show the number of samples in each class and
Table 2 P-values generated by significance testing of
BioHEL for the emPAI, ProteinProphet and combined
datasets
Dataset P-value
emPAI 1.64E-100
ProteinProphet 1.23E-220
ProteinProphet and emPAI combined 0
P-values were generated using a one-tailed permutation test. Classifications
were run on datasets with randomized sample labels, using leave-one-out
cross-validation; this was performed 50 times.
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the emPAI and ProteinProphet scores were useful in the
classification as some proteins, including triosepho-
sphate isomerase, MMP-3, IL-8 and HPLN1, are top
ranking proteins using both emPAI and ProteinProphet
values.
The interaction network generated from the Protein-
Prophet probabilities is shown in Figure 3. There are
particular proteins (those most connected to other pro-
teins) that can be identified from the network. These
proteins include matrix metalloproteinase-3 (MMP-3),
interleukin 8 (IL-8), HPLN1, matrix gla protein (MGP)
and APOE, and are detailed in Table 6. The interaction
network generated from the emPAI scores is shown in
Figure 4. In this network there are fewer highly con-
nected proteins, than in the ProteinProphet network, al-
though MMP-3 and IL-8 are again connected to many
other proteins. The fewer highly connected proteins in
the emPAI network could be due to some proteins hav-
ing similar emPAI scores but differing ProteinProphet
probabilities. Therefore, where in the ProteinProphet
network only one protein was suitable, in the emPAI
network multiple proteins gave the same results and
were interchangeable.Table 3 The ten mammalian proteins found most frequently
default control class, from the ProteinProphet dataset
IL-1β Car
Matrix metalloproteinase 3 (47.5) Matrix gla
Triosephosphate isomerase (19.6) Apolipopr
Enolase (4.56) Hyaluronan and proteo
interleukin 8 (2.61) Target of N
Leukocyte antigen CD37 (2.58) Phosphatidylinositol 3,4,5-tri
dual-specificity protei
Fibromodulin (2.58) Extracellular ma
Hyaluronan and proteoglycan link protein 1 (1.79) Alpha-1-an
Cartilage intermediate layer protein 1 (1.32) Kera
Metalloproteinase inhibitor 1 (1.22) Deco
Thrombospondin 1(1.13) Myotubularin-rel
The percentage of rules each protein was used in is shown in brackets.COMP is a noncollagenous ECM protein that is abun-
dantly expressed in articular cartilage and which has
been considered by other groups as a possible marker of
articular cartilage degradation. This protein was not in-
cluded in any top ranking protein lists, or in either net-
work generated, because COMP was found at similar
levels across all samples, regardless of the type of treat-
ment. Therefore the bioinformatics methods discussed
here are useful in determining proteins that may be suit-
able for use as putative biomarkers, rather than simply
proteins that are abundant. We also expected to detect
MMPs, a family of proteins expressed by chondrocytes
with roles in cartilage development, remodelling and dis-
ease [54]. Matrix metalloproteinase-3 (MMP-3), a surro-
gate biomarker of psoriatic and rheumatoid arthritis
[55,56], was pivotal in the classification of IL-1β samples.
MMP-3 is a proteolytic enzyme known to degrade com-
ponents of the ECM, including collagens and cartilage
proteoglycans and, as a result, was the top ranking pro-
tein for the IL-1β class. No other MMPs were
highlighted by the bioinformatics techniques applied.
interleukin 8 (IL-8) was dominant in the classification of
IL-1β and carprofen treated samples. IL-8 is the major
chemotactic factor released in response to pro-
inflammatory cytokines in synovial tissues from rheuma-
toid arthritis and osteoarthritis affected joints [57-59].
Matrix gla protein, involved in inhibition of calcification
in cartilage [51], was also frequently found in the Bio-
HEL rules from the analysis of the ProteinProhet dataset.
This protein was found in many samples across all treat-
ment groups, except for the carprofen + IL-1β group.
MMP-3, IL-8 and MGP were also the most connected
proteins in the ProteinProphet network. The inclusion
of proteins such as these in the top ranking lists and as
the most connected proteins, demonstrates the abilitiesin rules for each of the three classes, not including the
profen IL-1β and Carprofen
protein (52.5) interleukin 8 (93.1)
otein E (44.8) Matrix metalloproteinase 3 (6.87)
glycan link protein 1 (22.7) Pyruvate kinase isozyme M1 (5.59)
esh-SH3 (5.24) Protein S100-A1 (5.39)
sphosphate 3-phosphatase and
n phosphatase PTEN (5.1)
Bardet-Biedl syndrome 10 protein (5.35)
trix protein 1 (4.84) 50S ribosomal protein L29 (5.26)
titrypsin (2.89) Max-like protein X (5.08)
tin (2.82) Trypsin (4.82)
rin (2.59) Triosephosphate isomerase (4.74)
ated protein 1 (2.54) Alpha-2-HS-glycoprotein (4.62)
Table 4 The ten mammalian proteins found most frequently in rules for each of the three classes, not including the
default control class, from the emPAI dataset
IL-1β Carprofen IL-1β and Carprofen
Triosephosphate isomerase (73.4) Alpha-2-HS-glycoprotein (99.3) interleukin 8 (81.4)
Albumin (40.4) Tumor necrosis factor receptor superfamily member 11B (15.6) Lumican (14.9)
Serum amyloid A protein (23) Pseudouridylate synthase 7 homolog (15.1) Matrix metalloproteinase 3 (3.1)
Matrix metalloproteinase 3 (21.3) Lysozyme C (2) Desmin (2.6)
Vimentin-1 (9.8) Apolipoprotein E (1.8) Clusterin (2)
Vimentin (6) Matrix gla protein (1.8) Syndecan-4 (1.4)
Enolase B (5.9) Fibromodulin (1.4) Ribonuclease 4 (1)
Thrombospondin 1(5.3) Clusterin (1.3) Thrombospondin-3 (0.8)
Enolase A (3.4) Metalloproteinase inhibitor 1 (0.6) Enolase (0.6)
Keratin (3.8) Retinoblastoma-like protein 2 (0.4) Cartilage intermediate layer protein 1 (0.4)
The percentage of rules each protein was used in is shown in brackets.
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http://www.biomedcentral.com/1471-2474/14/349of these techniques aimed at identifying proteins in-
volved in cartilage degradation. There were other pro-
teins, such as APOE and HPLN1 that were found
frequently in the rules. However, the supplementary ta-
bles show they are not present in all the samples of any
group.
The proteins identified by this protocol were com-
pared to those found using the same proteomics proto-
col, but without the bioinformatics analysis, using
equine explant tissue [33]. There were proteins
highlighted in the equine study that were not in this ca-
nine study, including COMP, fibronectin and chon-
droadherin, because, whilst they were abundant in the
samples, they were not significantly different across the
different treatment groups. Therefore, the bioinformatics
methods used provide a way to focus on the most rele-
vant proteins.Table 5 The ten mammalian proteins found most frequently
default control class, from the ProteinProphet and emPAI com
IL-1β Carprofen
Triosephosphate isomerase (19.8) PP Apolipoprotein E (13.7)
Albumin (10) emPAI interleukin 8 (10.8)
Triosephosphate isomerase (9.3) emPAI interleukin 8 (9.9)
Matrix metalloproteinase 3 (7.6) PP Matrix gla protein (9.3)
Thrombospondin 1 (6.2) PP Hyaluronan and proteoglycan link
Serum amyloid A protein (3.5) emPAI Fibromodulin (7.4)
Matrix metalloproteinase 3 (3.4) emPAI Transmembrane protein PVRIG (4
Enolase B (3) emPAI Matrix gla protein (3.2)
Keratin (2.5) emPAI Hyaluronan and proteoglycan link
Enolase A (2.4) emPAI Clusterin (2)
The percentage of rules each protein was used in is shown in brackets. Alongside t
ProteinProphet probability (PP) or emPAI score.The data indicate that in the absence of IL-1β carpro-
fen had little effect on the cartilage explant secretome.
Therefore, proteins that aided in the classification may
have been included in the classification model, but are
not necessarily intrinsically involved in the processes be-
ing investigated. This resulted in some non-mammalian
proteins identified as top ranking proteins. It is possible
traces of contaminating proteins entered the analysis and
the proteins have been correctly identified. Alternatively,
proteins were incorrectly identified by Mascot; because
the selected proteins were not in the database used, in
which case the highest-ranking closest protein was used.
The major challenge faced by many proteomic studies
is the under representation of the lower abundance pro-
teins that are potentially of interest. This under repre-
sentation is due to the massive range of protein
abundance in complex biological samples such as serum,in rules for each of the three classes, not including the
bined dataset
IL-1β and Carprofen
PP interleukin 8 (33.8) emPAI
emPAI interleukin 8 (31) PP
PP Clusterin (5.8) emPAI
PP Matrix metalloproteinase 3 (5.7) PP
protein 1 (8.4) PP Thrombospondin-3 (2.4) emPAI
emPAI Matrix metalloproteinase 3 (2.2) emPAI
.6) PP Ribonuclease 4 (1.9) PP
emPAI Ribonuclease 4 (1.7) emPAI
protein 1 (2.3) emPAI Cartilage intermediate layer protein 1 (1) emPAI
emPAI Lumican (1) emPAI
he proteins the table reports whether the rules were using the protein with its
Table 6 Most connected proteins identified from the
ProteinProphet protein pairs network
Most connected proteins Description
interleukin 8 (IL-8) A chemotactic factor known to attract
neutrophils, basophils, and T-cells and is
involved in neutrophil activation. IL-8 is
released from a number of cell types in
response to an inflammatory stimulus [46].
Matrix metalloproteinase-3
(MMP-3)
MMP-3 can degrade fibronectin, laminin,
some gelatins, various collagens and
cartilage proteoglycans [47,48].
Apolipoprotein E (APOE) APOE mediates the binding, internalization,
and catabolism of lipoprotein
particles [49,50].
Matrix gla protein (MGP) MGP interacts with the matrix of bone
and cartilage and is thought to act as
an inhibitor of bone formation [51,52].
Hyaluronan and proteoglycan
link protein 1 (HPLN1)
HPLN1 stabilizes the aggregates of
proteoglycan monomers with hyaluronic
acid in the extracellular cartilage
matrix [53].
Figure 3 Protein interaction network generated from the top 100 BioHEL protein pairs for the ProteinProphet canine articular cartilage
dataset. The most frequently used protein pairs for IL-1β in blue, carprofen in red and carprofen + IL-1β in green.
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http://www.biomedcentral.com/1471-2474/14/349cerebrospinal fluid and urine or marginally less complex
samples like the secretome [60] with high abundant pro-
teins saturating the MS/MS with higher signal levels.
Proteins, such as COMP, are highly abundant in the car-
tilage and hinder identification of less abundant proteins
relevant to biological processes. Sample preparation
techniques such as proteome fractionation and deglyco-
sylation should enable the identification of less abundant
proteins and therefore more information could be un-
covered using these techniques.
As described, additional analyses were performed on a
number of top ranking proteins identified by these
methods. However, further analysis is required to inves-
tigate the individual proteins highlighted and other pro-
teins in the networks. This includes both laboratory-
based experiments to confirm the presence of individual
proteins and their levels within different sample types,
and further literature and pathway analyses to mine rele-
vant previously identified information.
Due to the nature of the machine learning methods
used, it would be more suitable to analyze larger datasets
Figure 4 Protein interaction network generated from the top 100 BioHEL protein pairs for the emPAI canine articular cartilage dataset.
The most frequently used protein pairs for IL-1β in blue, carprofen in red and carprofen + IL-1β in green.
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http://www.biomedcentral.com/1471-2474/14/349and therefore future work should include a similar study
on a larger scale, with more replicate samples and a lar-
ger number of animals.Conclusions
This study involved bioinformatic analysis of high
throughput proteomic data generated using an explant
model of cytokine-induced articular cartilage degrad-
ation. The approach described in this paper may be used
in future studies for identification of early structural
changes in cartilage and for drug testing, and screening
of novel anti-inflammatory compounds from natural
products. Extending our previous work with explant
models of articular cartilage, bioinformatics techniques
were applied to high throughput proteomics data to
identify proteins suitable for use as exploratory bio-
markers. This combination of laboratory-based and
computational methods has provided results, which ex-
perimental techniques alone could not have provided.
This proteomic and bioinformatics study has detected a
number of established ECM proteins, including MMP-3,
IL-8 and MGP, and therefore has shown the application
of these bioinformatics tools is suitable for this purposeand could be applied to proteomics data from other
areas.
Endnotes
ahttp://www.legislation.gov.uk/ukpga/1986/14/contents
bhttp://www.legislation.gov.uk/ukpga/1966/36
Additional files
Additional file 1: Table S1. Proteins identified by Mascot in the control
(untreated) samples with corresponding Mascot scores. The Mascot score
is a probability based score, used to determine the significance of a
protein match. The higher the score the less likely it is that the protein
match occurred by random.
Additional file 2: Table S2. Proteins identified by Mascot in the IL-1β
treated samples with their corresponding Mascot scores.
Additional file 3: Table S3. Proteins identified by Mascot in the
carprofen treated samples with their corresponding Mascot scores.
Additional file 4: Table S4. Proteins identified by Mascot in the
samples treated with a combination of carprofen and IL-1β and their
corresponding Mascot scores.
Additional file 5: Figure S1. SDS-PAGE protein profile of secretome
from dog one. a) control (1,2,3,4), IL-1β (5,6,7,8) b) control (1,2,3,4),
carprofen (5,6,7,8) c) control (1,2,3,4), IL-1β + carprofen (5,6,7,8). Molecular
weight markers (M) (in kDa) were Bio-Rad Precision Plus unstained
standards.
Swan et al. BMC Musculoskeletal Disorders 2013, 14:349 Page 11 of 12
http://www.biomedcentral.com/1471-2474/14/349Additional file 6: Figure S2. SDS-PAGE protein profile of secretome
from dog two. a) control (1,2,3,4), IL-1β (5,6,7,8) b) control (1,2,3,4),
carprofen (5,6,7,8) c) control (1,2,3,4), IL-1β + carprofen (5,6,7,8). Molecular
weight markers (M) (in kDa) were Bio-Rad Precision Plus unstained
standards. Lanes 1 – 8 each contain 14-μg protein. Lane 9 contains blank
loading buffer control. Arrows indicate differences in protein bands
between sample sets. Gels were silver stained.
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